Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.

You may also be interested in...



FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel

Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.

GSK’s Breo Breathing A Little Easier In Asthma, But More Studies Ahead

FDA advisory committee votes recommends Breo Ellipta for asthma in adults with post-approval safety study, but panel wants additional premarket efficacy and safety data for adolescents.

Breo Ellipta’s Adolescent Data Could Be Highest Hurdle For Asthma Claim

FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisors will cast separate votes March 19 on GSK’s ICS/LABA combo for patients 12-17 and for adults 18 and older.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel